Lukang Pharmaceutical: Wholly-owned subsidiary plans to invest 370 million yuan in the construction of a green biotechnology manufacturing project.

Lukang Pharmaceutical Announcement: The wholly-owned subsidiary of the company, Shandong Lukang Biomanufacturing Co., Ltd., intends to invest 370 million yuan to construct a green biomanufacturing project. This project has been approved by the company's board of directors and does not require submission for shareholder approval. The project will involve the construction of Class A and Class C plants and other facilities, with an expected construction period of 18 months. The preliminary feasibility study has been completed, and the subsequent three simultaneities procedures, including project establishment, safety assessment, and environmental assessment, will be initiated.